/
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 ( PD-1 ) inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma ( NPC ) and advance t…
The business is unprofitable at the operating level (-429.51% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 59.8% YoY with margins expanding 327.1pp.
Negative free cash flow of -$609M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$47M
▲ +59.8% YoY
Net Income (TTM)
$186M
▲ +489.4% YoY
Op. Margin
-366.55%
▲ +327.1pp YoY
ROIC
-154.92%
▲ +2120.6pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$609M
▼ -145.2% YoY
Op. Cash Flow (TTM)
-$171M
▼ -577.7% YoY
Net Debt
-$167M
Net Cash Position
Cash & Equiv.
$167M
5Y CAGR: -38.4%
Continue Research